Corcept Therapeutics | CORT - Current Liabilities


Corcept Therapeutics reported $177.68M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Alaunos Therapeutics USD 864K 269K Jun/2026
ANI Pharmaceuticals USD 328.72M 45.06M Sep/2026
Ardelyx USD 127.8M 4.42M Sep/2026
Aurora Cannabis CAD 73.43M 6.5M Jun/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Canopy Growth CAD 166.75M 8.31M Jun/2026
Corcept Therapeutics USD 177.68M 23.87M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
J&J USD 55.46B 562M Sep/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Merck USD 28.8B 1.07B Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 32.52B 777M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 126.1M 4.08M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
TG Therapeutics USD 260.53M 7.97M Sep/2026